Stock SANN SANTHERA PHARMACEUTICALS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 11:30:49 2024-04-23 am EDT 		5-day change 1st Jan Change
9.65 CHF +1.26% Intraday chart for Santhera Pharmaceuticals Holding AG +6.04% -1.63%
Apr. 17 Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis MT
Mar. 27 Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China MT

Business Summary

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Number of employees: 46

Sales per Business

CHF in Million2021Weight2022Weight Delta
Specialty Niche Products
100.0 %
-2 100.0 % 7 100.0 % -568.53%

Sales per region

CHF in Million2021Weight2022Weight Delta
Asia
149.7 %
-- 11 149.7 % -
Europe
-49.7 %
-2 100.0 % -4 -49.7 % +133.04%

Managers

Managers TitleAgeSince
Dario Eklund CEO
 Chief Executive Officer 56 19-11-30
Thomas Meier FOU
 Founder 62 04-09-06
Andrew P. Smith DFI
 Director of Finance/CFO 61 20-03-31
Marc Schrader CTO
 Chief Tech/Sci/R&D Officer - 22-08-31
Shabir Hasham CTO
 Chief Tech/Sci/R&D Officer - 14-12-31
Sarah Holmes-Klotz HRO
 Human Resources Officer - 22-02-28
Stephanie Brown PRN
 Corporate Officer/Principal - 21-11-30
Andreas Missy HRO
 Human Resources Officer - 19-12-31
Neville Kodkani SAM
 Sales & Marketing - 14-12-31
Oliver Strub LAW
 General Counsel 61 05-12-31

Members of the board

Members of the board TitleAgeSince
Thomas Meier FOU
 Founder 62 04-09-06
Philipp Gutzwiller BRD
 Director/Board Member 56 17-04-03
Otto Schwarz BRD
 Director/Board Member 68 23-06-26
Bradley Meyer BRD
 Director/Board Member - 23-06-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,624,907 8,929,941 ( 70.73 %) 0 70.73 %

Shareholders

NameEquities%Valuation
SANTHERA PHARMACEUTICALS HOLDING AG
15.86 %
2,001,327 15.86 % 22 M CHF
CATALYST PHARMACEUTICALS, INC.
11.21 %
1,414,688 11.21 % 15 M CHF
IDORSIA LTD
10.31 %
1,301,128 10.31 % 14 M CHF
Thomas Meier
0.1112 %
14,031 0.1112 % 152 196 CHF
C Worldwide Asset Management Fondsmæglerselskab A/S (Sweden)
0.0861 %
10,867 0.0861 % 117 876 CHF
Patrick Volkert Vink
0.0849 %
10,722 0.0849 % 116 303 CHF
Philipp Gutzwiller
0.0352 %
4,445 0.0352 % 48 215 CHF
CATAM Asset Management AG
0.0238 %
3,000 0.0238 % 32 541 CHF
Shabir Hasham
0.0210 %
2,646 0.0210 % 28 701 CHF
Dario Eklund
0.0198 %
2,500 0.0198 % 27 118 CHF

Holdings

NameEquities%Valuation
SANTHERA PHARMACEUTICALS HOLDING AG
15.86%
 2,001,327 15.86% 21,708,634 $

Company contact information

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24

4133, Pratteln

+41 61 906 89 50

http://www.santhera.com
address Santhera Pharmaceuticals Holding AG(SANN)

Group companies

NameCategory and Sector
Santhera Pharmaceuticals (Switzerland) Ltd.

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Specialty & Advanced Pharmaceuticals

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
9.65 CHF
Average target price
30 CHF
Spread / Average Target
+210.88%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SANTHERA PHARMACEUTICALS HOLDING AG Stock Santhera Pharmaceuticals Holding AG
-1.63% 96.31M
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.05% 9.18B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.33% 4.78B
YUHAN CORPORATION Stock Yuhan Corporation
+6.40% 3.87B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+26.98% 3.73B
INDIVIOR PLC Stock Indivior PLC
+28.27% 2.52B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.55% 2.27B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-25.02% 2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+5.82% 1.95B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SANN Stock
  4. Company Santhera Pharmaceuticals Holding AG